Loading...
XLON
4BB
Market cap204mUSD
Jun 16, Last price  
985.00GBP
1D
0.00%
1Q
-12.05%
IPO
154.19%
Name

4Basebio PLC

Chart & Performance

D1W1MN
No data to show
P/E
P/S
30,118.19
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
506k
+88.81%
202,000462,000338,000268,000506,000
Net income
-8m
L+48.83%
-423,000-719,000-3,235,000-5,150,000-7,665,000
CFO
-6m
L+31.34%
-269,000-1,022,000-2,740,000-4,704,000-6,178,000

Profile

4basebio PLC engages in the design, development, manufacturing, and supply of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company provides research kits, bulk enzymes, and other products, as well as licensing services; and AVV manufacturing services. It serves biotech, pharma, and contract development and manufacturing organization customers. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was incorporated in 2020 and is based in Cambridge, United Kingdom.
IPO date
Feb 17, 2021
Employees
61
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑12
Income
Revenues
506
88.81%
268
-20.71%
Cost of revenue
5,268
5,066
Unusual Expense (Income)
NOPBT
(4,762)
(4,798)
NOPBT Margin
Operating Taxes
(689)
(779)
Tax Rate
NOPAT
(4,073)
(4,019)
Net income
(7,665)
48.83%
(5,150)
59.20%
Dividends
Dividend yield
Proceeds from repurchase of equity
2
BB yield
0.00%
Debt
Debt current
392
415
Long-term debt
10,955
3,550
Deferred revenue
116
Other long-term liabilities
72
116
Net debt
8,278
(386)
Cash flow
Cash from operating activities
(6,178)
(4,704)
CAPEX
(871)
(1,941)
Cash from investing activities
(1,490)
(1,941)
Cash from financing activities
6,425
1,244
FCF
(4,262)
(5,336)
Balance
Cash
3,069
4,351
Long term investments
Excess cash
3,044
4,338
Stockholders' equity
(1,886)
5,726
Invested Capital
11,923
6,364
ROIC
ROCE
EV
Common stock shares outstanding
12,319
12,317
Price
6.80
-4.23%
7.10
15.45%
Market cap
83,771
-4.21%
87,454
15.45%
EV
92,049
87,068
EBITDA
(4,053)
(4,367)
EV/EBITDA
Interest
302
89
Interest/NOPBT